1. Phylogeny  
   Cyclin‐dependent kinase 4 (CDK4) is a serine/threonine protein kinase that is a well‐established member of the cyclin‐dependent kinase family within the larger CMGC kinase group. Comparative genomic studies and extensive sequence analyses have demonstrated that CDK4 is highly conserved among eukaryotes, with orthologous genes identified in unicellular fungi, invertebrates, and vertebrates alike (babisz2025exploringkinasesubstrate pages 177-180, equinet2004studiesonthe pages 106-109). Foundational studies by Manning et al. showed that the complement of protein kinases—including cell cycle regulators like CDK4—has been preserved since early eukaryotic evolution, with ancestral forms traceable to organisms dating back to the Last Eukaryotic Common Ancestor (LECA) (equinet2004studiesonthe pages 106-109, babisz2025exploringkinasesubstrate pages 177-180). In phylogenetic trees of the human kinome, CDK4 consistently clusters with other cyclin‐dependent kinases that function primarily during the G1 phase of the cell cycle. Its evolutionary relationships set it apart from kinases that predominantly regulate transcription or mediate stress responses, reflecting its specialized role in driving cell cycle progression (hunter2015theeukaryoticprotein pages 3-6, tong2012…proteinkinases pages 22-33). This conservation of the catalytic domain—as well as the regulatory motifs required for cyclin binding and activation—underscores the fundamental role of CDK4 in proliferative control across diverse eukaryotic lineages (babisz2025exploringkinasesubstrate pages 177-180).
2. Reaction Catalyzed  
   CDK4 catalyzes an ATP‐dependent phosphorylation reaction that is central to cell cycle regulation. The chemical reaction can be summarized as follows:  
     ATP + [protein]-(L‑serine or L‑threonine) → ADP + [protein]-(phospho‑L‑serine/threonine) + H⁺  
   In this reaction, the kinase facilitates the transfer of the γ-phosphate group from ATP to a serine or threonine residue in the substrate protein. This post–translational modification is crucial for modulating the activity, localization, and interaction properties of important regulatory proteins such as those in the retinoblastoma (RB) family. For example, when CDK4 phosphorylates RB1 within the CDK4–cyclin D complex, it results in the disruption of RB1’s interaction with E2F transcription factors, thereby enabling the subsequent transcription of genes essential for progressing through the G1/S checkpoint (babisz2025exploringkinasesubstrate pages 180-183, johnson2023anatlasof pages 10-11).
3. Cofactor Requirements  
   The catalytic function of CDK4 is dependent on specific cofactors, with magnesium ions (Mg²⁺) being indispensable for its activity. Mg²⁺ acts by coordinating with the phosphate groups of ATP, thereby neutralizing negative charges and facilitating the proper orientation of the γ-phosphate for effective transfer to the substrate’s hydroxyl group. This requirement for Mg²⁺ is a canonical feature among serine/threonine protein kinases, ensuring that the phosphorylation reaction proceeds with both fidelity and efficiency (equinet2004studiesonthe pages 106-109, babisz2025exploringkinasesubstrate pages 177-180, johnson2023anatlasof pages 10-11).
4. Substrate Specificity  
   Recent high-throughput substrate profiling studies have clarified the substrate specificity of CDK4. These studies reveal that CDK4 exhibits a marked preference for phosphorylating substrates that contain a serine or threonine residue immediately followed by a proline residue—a motif commonly referred to as a [S/T]–P motif. Moreover, refinements in the substrate consensus sequence indicate that there is frequently an additional preference for a basic residue, such as lysine or arginine, at the +3 position relative to the phosphorylatable residue. In essence, the approximate consensus sequence for substrates phosphorylated by CDK4 can be described as [S/T]–P–x–[K/R], where “x” represents any intervening amino acid (johnson2023anatlasof pages 3-4, babisz2025exploringkinasesubstrate pages 183-186, sugiyama2019largescalediscoveryof pages 6-8). This motif ensures that CDK4 targets physiological substrates—such as various members of the RB protein family and regulatory proteins like SMAD3—with high substrate fidelity and precision.
5. Structure  
   The three-dimensional architecture of CDK4 conforms to the canonical domain organization observed in cyclin-dependent kinases. The kinase domain is organized into two lobes: a smaller N-terminal lobe and a larger C-terminal lobe, connected by a flexible hinge region that facilitates the proper positioning of ATP. Within the N-terminal lobe, a prominent feature is the glycine-rich loop, also known as the p-loop, which plays a central role in binding ATP by clamping its phosphate groups. A key catalytic lysine residue is situated in this lobe and is instrumental in stabilizing ATP through electrostatic interactions.  
   The larger C-terminal lobe is characterized by a dominant alpha-helical structure and houses the activation loop (T-loop), a critical regulatory segment. In CDK4, the activation loop contains a threonine residue at position 172 whose phosphorylation by a CDK-activating kinase (CAK) is essential to stabilize the active conformation of the kinase. Another hallmark of the structure is the C-helix within the N-terminal lobe. In many activated cyclin-dependent kinases, the C-helix is repositioned inward to form a salt bridge with the catalytic lysine, a rearrangement necessary for aligning catalytic residues during phosphotransfer. Although full-length high-resolution structures of the intact CDK4–cyclin D complex remain challenging, available crystallographic data—as exemplified by studies that have resolved modified constructs of CDK4 (with engineered truncations or residue substitutions to permit crystallization)—suggest that binding of D-type cyclins prompts subtle yet essential conformational rearrangements in both the C-helix and the activation loop, thus promoting a configuration conducive to catalysis (takaki2009thestructureof pages 1-1, takaki2009thestructureof pages 3-3, liu2021leveragingdiversedata pages 28-33).  
   Additionally, a hydrophobic spine comprising a contiguous array of nonpolar residues traverses the kinase domain, contributing to the structural integrity and facilitating allosteric communication necessary for the transition between inactive and active states. The regions outside the core kinase domain also include interaction motifs that mediate specific binding to various D-type cyclins (D1, D2, and D3), thereby ensuring the spatiotemporal regulation of CDK4 activity (babisz2025exploringkinasesubstrate pages 177-180, liu2021leveragingdiversedata pages 28-33).
6. Regulation  
   CDK4 activity is subject to a complex regulatory network that integrates multiple positive and negative signals to ensure precise control over cell cycle progression. A primary event in its activation is the binding of D-type cyclins, an association that is essential for the assembly of an active holoenzyme complex. Cyclin binding itself induces conformational changes within CDK4 that result in an increased accessibility of the ATP-binding cleft and primes the kinase for further activation processes. However, cyclin binding alone does not confer full catalytic competence to CDK4. Full activation is achieved through phosphorylation of the activation loop, particularly at threonine 172; this phosphorylation event, catalyzed by a CDK-activating kinase (CAK), stabilizes the activation loop in a conformation that is permissive for substrate binding and catalytic turnover (babisz2025exploringkinasesubstrate pages 177-180, johnson2023anatlasof pages 10-11).  
   In addition to activating phosphorylation, CDK4 is tightly regulated by a variety of inhibitory proteins. Members of the INK4 family, notably p16INK4a, bind directly to CDK4 and prevent its association with cyclin D, effectively blocking the formation of the active complex. This inhibitory interaction is critical for ensuring that CDK4 is only active under conditions where appropriate mitogenic signals are present. Moreover, the Cip/Kip family protein p27^Kip1 has been observed to associate with the cyclin D–CDK4 complex, where it can either stabilize the complex or inhibit its activity depending on its phosphorylation status. For instance, studies have reported that phosphorylation of p27^Kip1 at specific tyrosine residues induces a conformational change that modulates its affinity for the complex and its overall inhibitory potency (babisz2025exploringkinasesubstrate pages 183-186, baker2012cdk4akey pages 2-3, guiley2019p27allostericallyactivates pages 1-3).  
   Beyond protein–protein interactions, additional layers of regulation involve post–translational modifications. Ubiquitination processes help control the cellular concentration and turnover of CDK4, thereby preventing its accumulation when it is not required for cell cycle progression. Chaperone complexes such as Hsp90/Cdc37 also play a role by assisting in the proper folding and stabilization of CDK4, further ensuring the formation of a functional CDK4–cyclin D complex (babisz2025exploringkinasesubstrate pages 189-190, liu2021leveragingdiversedata pages 33-36, bockstaele2006regulationofcdk4 pages 1-2).
7. Function  
   The primary biological function of CDK4 is to regulate cell cycle progression through its action during the G1 phase, thereby controlling the transition into the S phase. Upon mitogenic stimulation, an upregulation of D-type cyclins occurs, leading to the formation of active CDK4–cyclin D complexes. These complexes phosphorylate critical substrates, most notably the retinoblastoma protein (RB1). Phosphorylation of RB1 reduces its ability to bind E2F transcription factors, releasing these factors to activate the transcription of genes necessary for DNA synthesis and S-phase entry (babisz2025exploringkinasesubstrate pages 177-180, johnson2023anatlasof pages 3-4).  
   In addition to RB1, CDK4 also phosphorylates other substrates, such as SMAD3. Phosphorylation of SMAD3 leads to the repression of its transcriptional activity, which links cell cycle regulation with the modulation of specific gene expression programs. CDK4 is commonly found as part of a ternary complex that includes cyclin D and the CDK inhibitor CDKN1B (p27^Kip1). This complex is essential not only for the catalytic function of CDK4 but also for its proper nuclear localization, ensuring that phosphorylation of nuclear substrates such as RB1 is effectively accomplished (babisz2025exploringkinasesubstrate pages 183-186, baker2022cdk4amaster pages 1-2, suryadinata2010controlofcell pages 3-4).  
   Furthermore, CDK4 serves as a critical integrator of mitogenic and antimitogenic signals within the cell. Its activity is modulated by external growth factor stimuli as well as internal cell cycle checkpoints that ensure division only when conditions are favorable. CDK4 is ubiquitously expressed in proliferative tissues and is essential for normal developmental processes as well as for maintaining tissue homeostasis in adult organisms (babisz2025exploringkinasesubstrate pages 177-180, johnson2023anatlasof pages 3-4).
8. Other Comments  
   Owing to its fundamental role in cell cycle regulation, aberrations in CDK4 activity are frequently associated with oncogenesis. Overexpression of D-type cyclins, amplification of the CDK4 gene, or loss of inhibitory proteins such as p16INK4a can lead to uncontrolled kinase activity, resulting in enhanced phosphorylation of RB1 and the subsequent deregulation of cell proliferation. Such dysregulation is implicated in various cancers, including breast cancer, melanoma, and several sarcomas (baker2012cdk4akey pages 1-2, peyressatre2015targetingcyclindependentkinases pages 6-8, sielecki2000cyclindependentkinaseinhibitors pages 2-4).  
   The clinical relevance of CDK4 is further underscored by the development and approval of small molecule inhibitors that target CDK4 and its closely related kinase CDK6. Compounds such as palbociclib, ribociclib, and abemaciclib are ATP-competitive inhibitors that function by preventing the phosphorylation of downstream substrates like RB1, thereby enforcing a G1-phase arrest in cancer cells (baker2012cdk4akey pages 1-2, peyressatre2015targetingcyclindependentkinases pages 6-8). In addition to chemical inhibitors, emerging strategies—such as targeted protein degradation techniques—are being explored to modulate CDK4 levels and activity, reflecting the ongoing effort to refine therapeutic interventions against cancers driven by cell cycle dysregulation (baker2012cdk4akey pages 10-11, peyressatre2015targetingcyclindependentkinases pages 6-8).  
   Within the context of diagnostic applications, specific mutations in CDK4 that disrupt its inhibitory interactions with p16INK4a have been identified; such mutations are known to lead to constitutive kinase activation. These genetic alterations serve as both biomarkers and therapeutic targets, as they often confer sensitivity to CDK4/6 inhibitors in clinical settings (baker2012cdk4akey pages 10-11, peyressatre2015targetingcyclindependentkinases pages 6-8, sielecki2000cyclindependentkinaseinhibitors pages 2-4).
9. References
10. babisz2025exploringkinasesubstrate pages 177-180
11. babisz2025exploringkinasesubstrate pages 180-183
12. babisz2025exploringkinasesubstrate pages 183-186
13. babisz2025exploringkinasesubstrate pages 189-190
14. equinet2004studiesonthe pages 106-109
15. hunter2015theeukaryoticprotein pages 3-6
16. johnson2023anatlasof pages 1-2
17. johnson2023anatlasof pages 3-4
18. johnson2023anatlasof pages 10-11
19. kınalı2019leveragingthehuman pages 14-18
20. liu2021leveragingdiversedata pages 28-33
21. liu2021leveragingdiversedata pages 33-36
22. sugiyama2019largescalediscoveryof pages 6-8
23. tong2012…proteinkinases pages 22-33
24. baker2012cdk4akey pages 1-2
25. baker2012cdk4akey pages 2-3
26. baker2012cdk4akey pages 8-9
27. baker2022cdk4amaster pages 1-2
28. baker2022cdk4amaster pages 2-4
29. baker2022cdk4amaster pages 8-9
30. bockstaele2006regulationofcdk4 pages 1-2
31. dickson2014molecularpathwayscdk4 pages 1-2
32. ding2020therolesof pages 1-3
33. echalier2010recentdevelopmentsin pages 7-8
34. guiley2019p27allostericallyactivates pages 1-3
35. hanks1995theeukaryoticprotein pages 20-21
36. jha2025deeplearningcoupledproximity pages 24-26
37. malumbres2014cyclindependentkinases pages 5-6
38. peyressatre2015targetingcyclindependentkinases pages 1-4
39. peyressatre2015targetingcyclindependentkinases pages 6-8
40. shafiq2011molecularmodellingand pages 30-35
41. sharp2024manuscriptwithfigures pages 6-10
42. sielecki2000cyclindependentkinaseinhibitors pages 2-4
43. suryadinata2010controlofcell pages 3-4
44. suryadinata2010controlofcell pages 9-10
45. takaki2009thestructureof pages 1-1
46. takaki2009thestructureof pages 3-3
47. vanarsdale2015molecularpathwaystargeting pages 2-3

References

1. (babisz2025exploringkinasesubstrate pages 177-180): C Babisz. Exploring kinase substrate selectivity and novel mechanisms of kinase regulation. Unknown journal, 2025.
2. (babisz2025exploringkinasesubstrate pages 180-183): C Babisz. Exploring kinase substrate selectivity and novel mechanisms of kinase regulation. Unknown journal, 2025.
3. (babisz2025exploringkinasesubstrate pages 183-186): C Babisz. Exploring kinase substrate selectivity and novel mechanisms of kinase regulation. Unknown journal, 2025.
4. (babisz2025exploringkinasesubstrate pages 189-190): C Babisz. Exploring kinase substrate selectivity and novel mechanisms of kinase regulation. Unknown journal, 2025.
5. (baker2012cdk4akey pages 1-2): S. J. Baker and E. P. Reddy. Cdk4: a key player in the cell cycle, development, and cancer. Genes & Cancer, 3:658-669, Nov 2012. URL: https://doi.org/10.1177/1947601913478972, doi:10.1177/1947601913478972. This article has 213 citations.
6. (baker2012cdk4akey pages 2-3): S. J. Baker and E. P. Reddy. Cdk4: a key player in the cell cycle, development, and cancer. Genes & Cancer, 3:658-669, Nov 2012. URL: https://doi.org/10.1177/1947601913478972, doi:10.1177/1947601913478972. This article has 213 citations.
7. (baker2012cdk4akey pages 8-9): S. J. Baker and E. P. Reddy. Cdk4: a key player in the cell cycle, development, and cancer. Genes & Cancer, 3:658-669, Nov 2012. URL: https://doi.org/10.1177/1947601913478972, doi:10.1177/1947601913478972. This article has 213 citations.
8. (baker2022cdk4amaster pages 1-2): Stacey J. Baker, Poulikos I. Poulikakos, Hanna Y. Irie, Samir Parekh, and E. Premkumar Reddy. Cdk4: a master regulator of the cell cycle and its role in cancer. Genes & Cancer, 13:21-45, Aug 2022. URL: https://doi.org/10.18632/genesandcancer.221, doi:10.18632/genesandcancer.221. This article has 65 citations.
9. (baker2022cdk4amaster pages 2-4): Stacey J. Baker, Poulikos I. Poulikakos, Hanna Y. Irie, Samir Parekh, and E. Premkumar Reddy. Cdk4: a master regulator of the cell cycle and its role in cancer. Genes & Cancer, 13:21-45, Aug 2022. URL: https://doi.org/10.18632/genesandcancer.221, doi:10.18632/genesandcancer.221. This article has 65 citations.
10. (baker2022cdk4amaster pages 8-9): Stacey J. Baker, Poulikos I. Poulikakos, Hanna Y. Irie, Samir Parekh, and E. Premkumar Reddy. Cdk4: a master regulator of the cell cycle and its role in cancer. Genes & Cancer, 13:21-45, Aug 2022. URL: https://doi.org/10.18632/genesandcancer.221, doi:10.18632/genesandcancer.221. This article has 65 citations.
11. (bockstaele2006regulationofcdk4 pages 1-2): Laurence Bockstaele, Katia Coulonval, Hugues Kooken, Sabine Paternot, and Pierre P Roger. Regulation of cdk4. Cell Division, 1:25-25, Nov 2006. URL: https://doi.org/10.1186/1747-1028-1-25, doi:10.1186/1747-1028-1-25. This article has 97 citations and is from a peer-reviewed journal.
12. (dickson2014molecularpathwayscdk4 pages 1-2): Mark A. Dickson. Molecular pathways: cdk4 inhibitors for cancer therapy. Clinical Cancer Research, 20:3379-3383, Jun 2014. URL: https://doi.org/10.1158/1078-0432.ccr-13-1551, doi:10.1158/1078-0432.ccr-13-1551. This article has 323 citations and is from a highest quality peer-reviewed journal.
13. (ding2020therolesof pages 1-3): L. Ding, Jiaqi Cao, Wen-Lien Lin, Hongjian Chen, Xianhui Xiong, Hongshun Ao, Min Yu, Jie Lin, and Qing-hua Cui. The roles of cyclin-dependent kinases in cell-cycle progression and therapeutic strategies in human breast cancer. International Journal of Molecular Sciences, 21:1960, Mar 2020. URL: https://doi.org/10.3390/ijms21061960, doi:10.3390/ijms21061960. This article has 610 citations and is from a peer-reviewed journal.
14. (echalier2010recentdevelopmentsin pages 7-8): Aude Echalier, Jane A. Endicott, and Martin E.M. Noble. Recent developments in cyclin-dependent kinase biochemical and structural studies. Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics, 1804:511-519, Mar 2010. URL: https://doi.org/10.1016/j.bbapap.2009.10.002, doi:10.1016/j.bbapap.2009.10.002. This article has 162 citations.
15. (equinet2004studiesonthe pages 106-109): L Equinet. Studies on the kinome of plasmodium falciparum and biochemical characterization of atypical protein kinases. Unknown journal, 2004.
16. (guiley2019p27allostericallyactivates pages 1-3): Keelan Z. Guiley, Jack W. Stevenson, Kevin Lou, Krister J. Barkovich, Vishnu Kumarasamy, Tilini U. Wijeratne, Katharine L. Bunch, Sarvind Tripathi, Erik S. Knudsen, Agnieszka K. Witkiewicz, Kevan M. Shokat, and Seth M. Rubin. P27 allosterically activates cyclin-dependent kinase 4 and antagonizes palbociclib inhibition. Science, Dec 2019. URL: https://doi.org/10.1126/science.aaw2106, doi:10.1126/science.aaw2106. This article has 216 citations and is from a highest quality peer-reviewed journal.
17. (hanks1995theeukaryoticprotein pages 20-21): Steven K. Hanks and Tony Hunter. The eukaryotic protein kinase superfamily: kinase (catalytic) domain structure and classification 1. The FASEB Journal, 9:576-596, May 1995. URL: https://doi.org/10.1096/fasebj.9.8.7768349, doi:10.1096/fasebj.9.8.7768349. This article has 3987 citations.
18. (hunter2015theeukaryoticprotein pages 3-6): Tony Hunter and Gerard Manning. The eukaryotic protein kinase superfamily and the emergence of receptor tyrosine kinases. Receptor Tyrosine Kinases: Structure, Functions and Role in Human Disease, pages 1-15, Oct 2015. URL: https://doi.org/10.1007/978-1-4939-2053-2\_1, doi:10.1007/978-1-4939-2053-2\_1. This article has 6 citations.
19. (jha2025deeplearningcoupledproximity pages 24-26): Kanchan Jha, Daichi Shonai, Aditya Parekh, Akiyoshi Uezu, Tomoyuki Fujiyama, Hikari Yamamoto, Pooja Parameswaran, Masashi Yanagisawa, Rohit Singh, and Scott H. Soderling. Deep learning-coupled proximity proteomics to deconvolve kinase signaling in vivo. BioRxiv, Apr 2025. URL: https://doi.org/10.1101/2025.04.27.650849, doi:10.1101/2025.04.27.650849. This article has 0 citations.
20. (johnson2023anatlasof pages 1-2): Jared L. Johnson, Tomer M. Yaron, Emily M. Huntsman, Alexander Kerelsky, Junho Song, Amit Regev, Ting-Yu Lin, Katarina Liberatore, Daniel M. Cizin, Benjamin M. Cohen, Neil Vasan, Yilun Ma, Konstantin Krismer, Jaylissa Torres Robles, Bert van de Kooij, Anne E. van Vlimmeren, Nicole Andrée-Busch, Norbert F. Käufer, Maxim V. Dorovkov, Alexey G. Ryazanov, Yuichiro Takagi, Edward R. Kastenhuber, Marcus D. Goncalves, Benjamin D. Hopkins, Olivier Elemento, Dylan J. Taatjes, Alexandre Maucuer, Akio Yamashita, Alexei Degterev, Mohamed Uduman, Jingyi Lu, Sean D. Landry, Bin Zhang, Ian Cossentino, Rune Linding, John Blenis, Peter V. Hornbeck, Benjamin E. Turk, Michael B. Yaffe, and Lewis C. Cantley. An atlas of substrate specificities for the human serine/threonine kinome. Nature, 613:759-766, Jan 2023. URL: https://doi.org/10.1038/s41586-022-05575-3, doi:10.1038/s41586-022-05575-3. This article has 416 citations and is from a highest quality peer-reviewed journal.
21. (johnson2023anatlasof pages 10-11): Jared L. Johnson, Tomer M. Yaron, Emily M. Huntsman, Alexander Kerelsky, Junho Song, Amit Regev, Ting-Yu Lin, Katarina Liberatore, Daniel M. Cizin, Benjamin M. Cohen, Neil Vasan, Yilun Ma, Konstantin Krismer, Jaylissa Torres Robles, Bert van de Kooij, Anne E. van Vlimmeren, Nicole Andrée-Busch, Norbert F. Käufer, Maxim V. Dorovkov, Alexey G. Ryazanov, Yuichiro Takagi, Edward R. Kastenhuber, Marcus D. Goncalves, Benjamin D. Hopkins, Olivier Elemento, Dylan J. Taatjes, Alexandre Maucuer, Akio Yamashita, Alexei Degterev, Mohamed Uduman, Jingyi Lu, Sean D. Landry, Bin Zhang, Ian Cossentino, Rune Linding, John Blenis, Peter V. Hornbeck, Benjamin E. Turk, Michael B. Yaffe, and Lewis C. Cantley. An atlas of substrate specificities for the human serine/threonine kinome. Nature, 613:759-766, Jan 2023. URL: https://doi.org/10.1038/s41586-022-05575-3, doi:10.1038/s41586-022-05575-3. This article has 416 citations and is from a highest quality peer-reviewed journal.
22. (johnson2023anatlasof pages 3-4): Jared L. Johnson, Tomer M. Yaron, Emily M. Huntsman, Alexander Kerelsky, Junho Song, Amit Regev, Ting-Yu Lin, Katarina Liberatore, Daniel M. Cizin, Benjamin M. Cohen, Neil Vasan, Yilun Ma, Konstantin Krismer, Jaylissa Torres Robles, Bert van de Kooij, Anne E. van Vlimmeren, Nicole Andrée-Busch, Norbert F. Käufer, Maxim V. Dorovkov, Alexey G. Ryazanov, Yuichiro Takagi, Edward R. Kastenhuber, Marcus D. Goncalves, Benjamin D. Hopkins, Olivier Elemento, Dylan J. Taatjes, Alexandre Maucuer, Akio Yamashita, Alexei Degterev, Mohamed Uduman, Jingyi Lu, Sean D. Landry, Bin Zhang, Ian Cossentino, Rune Linding, John Blenis, Peter V. Hornbeck, Benjamin E. Turk, Michael B. Yaffe, and Lewis C. Cantley. An atlas of substrate specificities for the human serine/threonine kinome. Nature, 613:759-766, Jan 2023. URL: https://doi.org/10.1038/s41586-022-05575-3, doi:10.1038/s41586-022-05575-3. This article has 416 citations and is from a highest quality peer-reviewed journal.
23. (kınalı2019leveragingthehuman pages 14-18): M Kınalı. Leveraging the human kinome for anticancer agent cytotoxicity potency prediction. Unknown journal, 2019.
24. (liu2021leveragingdiversedata pages 28-33): C Liu. Leveraging diverse data modalities to study kinase inhibitor polypharmacology. Unknown journal, 2021.
25. (liu2021leveragingdiversedata pages 33-36): C Liu. Leveraging diverse data modalities to study kinase inhibitor polypharmacology. Unknown journal, 2021.
26. (malumbres2014cyclindependentkinases pages 5-6): Marcos Malumbres. Cyclin-dependent kinases. Genome Biology, 15:122-122, Jun 2014. URL: https://doi.org/10.1186/gb4184, doi:10.1186/gb4184. This article has 1880 citations and is from a highest quality peer-reviewed journal.
27. (peyressatre2015targetingcyclindependentkinases pages 1-4): Marion Peyressatre, Camille Prével, Morgan Pellerano, and May Morris. Targeting cyclin-dependent kinases in human cancers: from small molecules to peptide inhibitors. Cancers, 7:179-237, Jan 2015. URL: https://doi.org/10.3390/cancers7010179, doi:10.3390/cancers7010179. This article has 402 citations and is from a peer-reviewed journal.
28. (peyressatre2015targetingcyclindependentkinases pages 6-8): Marion Peyressatre, Camille Prével, Morgan Pellerano, and May Morris. Targeting cyclin-dependent kinases in human cancers: from small molecules to peptide inhibitors. Cancers, 7:179-237, Jan 2015. URL: https://doi.org/10.3390/cancers7010179, doi:10.3390/cancers7010179. This article has 402 citations and is from a peer-reviewed journal.
29. (shafiq2011molecularmodellingand pages 30-35): MI Shafiq. Molecular modelling and bioinformatics studies of cdk4 and related proteins. Unknown journal, 2011. URL: https://doi.org/10104464/1, doi:10104464/1.
30. (sielecki2000cyclindependentkinaseinhibitors pages 2-4): Thais M. Sielecki, John F. Boylan, Pamela A. Benfield, and George L. Trainor. Cyclin-dependent kinase inhibitors: useful targets in cell cycle regulation. Journal of medicinal chemistry, 43 1:1-18, Jan 2000. URL: https://doi.org/10.1021/jm990256j, doi:10.1021/jm990256j. This article has 455 citations and is from a highest quality peer-reviewed journal.
31. (sugiyama2019largescalediscoveryof pages 6-8): Naoyuki Sugiyama, Haruna Imamura, and Yasushi Ishihama. Large-scale discovery of substrates of the human kinome. Scientific Reports, Jul 2019. URL: https://doi.org/10.1038/s41598-019-46385-4, doi:10.1038/s41598-019-46385-4. This article has 119 citations and is from a poor quality or predatory journal.
32. (suryadinata2010controlofcell pages 3-4): Randy Suryadinata, Martin Sadowski, and Boris Sarcevic. Control of cell cycle progression by phosphorylation of cyclin-dependent kinase (cdk) substrates. Bioscience reports, 30 4:243-55, Aug 2010. URL: https://doi.org/10.1042/bsr20090171, doi:10.1042/bsr20090171. This article has 227 citations and is from a peer-reviewed journal.
33. (suryadinata2010controlofcell pages 9-10): Randy Suryadinata, Martin Sadowski, and Boris Sarcevic. Control of cell cycle progression by phosphorylation of cyclin-dependent kinase (cdk) substrates. Bioscience reports, 30 4:243-55, Aug 2010. URL: https://doi.org/10.1042/bsr20090171, doi:10.1042/bsr20090171. This article has 227 citations and is from a peer-reviewed journal.
34. (takaki2009thestructureof pages 1-1): T. Takaki, A. Echalier, N. R. Brown, T. Hunt, J. A. Endicott, and M. E. M. Noble. The structure of cdk4/cyclin d3 has implications for models of cdk activation. Proceedings of the National Academy of Sciences, 106:4171-4176, Mar 2009. URL: https://doi.org/10.1073/pnas.0809674106, doi:10.1073/pnas.0809674106. This article has 147 citations.
35. (takaki2009thestructureof pages 3-3): T. Takaki, A. Echalier, N. R. Brown, T. Hunt, J. A. Endicott, and M. E. M. Noble. The structure of cdk4/cyclin d3 has implications for models of cdk activation. Proceedings of the National Academy of Sciences, 106:4171-4176, Mar 2009. URL: https://doi.org/10.1073/pnas.0809674106, doi:10.1073/pnas.0809674106. This article has 147 citations.
36. (tong2012…proteinkinases pages 22-33): M Tong. … protein kinases for solution nmr spectroscopy and the structural mechanism of inhibition and activation of an oncogenic calcium calmodulin dependent protein kinase. Unknown journal, 2012.
37. (vanarsdale2015molecularpathwaystargeting pages 2-3): Todd VanArsdale, Chris Boshoff, Kim T. Arndt, and Robert T. Abraham. Molecular pathways: targeting the cyclin d–cdk4/6 axis for cancer treatment. Clinical Cancer Research, 21:2905-2910, Jun 2015. URL: https://doi.org/10.1158/1078-0432.ccr-14-0816, doi:10.1158/1078-0432.ccr-14-0816. This article has 430 citations and is from a highest quality peer-reviewed journal.